Hermetica Superfood Encyclopedia
The Short Answer
Escherichia coli Nissle 1917 is a non-pathogenic probiotic strain that produces antimicrobial compounds like microcins and colicins to inhibit harmful bacteria. This strain strengthens intestinal barrier function through enhanced tight junction proteins and modulates immune responses via dendritic cell activation.
CategoryProbiotic & Fiber
GroupOther
Evidence LevelStrong
Primary KeywordEscherichia coli Nissle 1917 benefits
Synergy Pairings3
Escherichia coli Nissle 1917 — botanical close-up
Health Benefits
Supports gut health by balancing intestinal flora, which enhances nutrient absorption and reduces digestive discomfort. - May prevent and treat gastrointestinal disorders by inhibiting the growth of harmful bacteria, reducing the risk of infections. - Enhances immune function by stimulating the production of protective antibodies, lowering the risk of infections. - Reduces inflammation by modulating cytokine production, which can alleviate symptoms of inflammatory bowel diseases. - Supports mental health by producing neurotransmitters like serotonin, which can improve mood and reduce anxiety. - Enhances skin health by maintaining a balanced gut microbiome, which is linked to reduced acne and eczema flare-ups. - Supports cardiovascular health by reducing cholesterol levels, as shown in studies where participants experienced a 10% reduction in LDL cholesterol.
Origin & History
Natural habitat
Escherichia coli Nissle 1917 is a non-pathogenic probiotic strain isolated by Dr. Alfred Nissle in 1917. It is recognized for its ability to colonize the human gut and promote health.
“Discovered during World War I, Escherichia coli Nissle 1917 has been used in Europe as a therapeutic probiotic for over a century, particularly in Germany.”Traditional Medicine
Scientific Research
Escherichia coli Nissle 1917 has been extensively studied and is one of the most researched probiotic strains for treating gastrointestinal disorders, with numerous clinical trials supporting its efficacy.
Preparation & Dosage
Traditional preparation
Recommended dosage is 1 to 2 capsules (around 10 billion CFU) per day. Consult a healthcare provider before use.
Nutritional Profile
- Contains live, beneficial bacteria. - Free from artificial ingredients. - Typically available in capsule or liquid form.
How It Works
Mechanism of Action
E. coli Nissle 1917 produces antimicrobial peptides including microcins H47 and M, along with colicins that directly inhibit pathogenic bacteria growth. The strain enhances intestinal barrier function by upregulating tight junction proteins claudin-1 and ZO-1, while stimulating dendritic cells to produce anti-inflammatory cytokine IL-10. It also competes with pathogens for iron through siderophore production and adhesion sites on intestinal epithelial cells.
Clinical Evidence
Clinical trials demonstrate E. coli Nissle 1917's efficacy in maintaining ulcerative colitis remission, with studies showing comparable effectiveness to mesalamine in 327 patients over 12 months. A randomized controlled trial of 116 patients found significant reduction in IBS symptoms after 6 weeks of treatment. Meta-analyses indicate moderate evidence for preventing traveler's diarrhea and reducing antibiotic-associated diarrhea incidence. However, most studies are small-scale with heterogeneous populations, requiring larger trials for definitive therapeutic recommendations.
Safety & Interactions
E. coli Nissle 1917 is generally well-tolerated with mild gastrointestinal side effects like bloating or gas in <5% of users. The strain may theoretically interact with immunosuppressive medications by enhancing immune responses, though no specific drug interactions are documented. It should be avoided in severely immunocompromised patients, those with central venous catheters, or acute pancreatitis due to rare bacteremia risk. Pregnancy and breastfeeding safety data are limited, warranting caution in these populations.
Synergy Stack
Hermetica Formulation Heuristic
Also Known As
Escherichia coli Nissle 1917EcNE. coli NissleDSM 6601MutaflorNissle 1917Probiotic E. coli strain
Frequently Asked Questions
What is the typical dosage of E. coli Nissle 1917?
The standard therapeutic dose is 2.5-25 billion CFU daily, typically taken as enteric-coated capsules to survive stomach acid. Clinical studies commonly use 5-10 billion CFU once daily for maintenance therapy.
How long does it take for E. coli Nissle 1917 to work?
Initial gut colonization occurs within 3-7 days, with measurable improvements in digestive symptoms typically appearing after 2-4 weeks of consistent use. Full therapeutic benefits for inflammatory conditions may require 6-12 weeks of supplementation.
Can E. coli Nissle 1917 cause infections?
While extremely rare, isolated cases of bacteremia have occurred in severely immunocompromised patients or those with compromised gut barriers. The strain lacks typical E. coli virulence factors and is considered safe for healthy individuals.
Should E. coli Nissle 1917 be taken with antibiotics?
It should be taken at least 2 hours apart from antibiotics to prevent bacterial killing. Some studies suggest it may help prevent antibiotic-associated diarrhea when used concurrently with appropriate timing.
What makes E. coli Nissle 1917 different from other probiotics?
Unlike typical Lactobacillus or Bifidobacterium strains, it's a Gram-negative bacterium that produces unique antimicrobial compounds like microcins. It has stronger anti-inflammatory effects and better colonization persistence in the large intestine compared to most commercial probiotics.
Is E. coli Nissle 1917 safe for children and infants?
E. coli Nissle 1917 has been used safely in pediatric populations, including infants, and is particularly beneficial for preventing antibiotic-associated diarrhea in children. However, dosing should be adjusted based on age and clinical guidance from a healthcare provider. It is generally considered safe for infants and children when administered under medical supervision.
Does E. coli Nissle 1917 interact with common medications?
E. coli Nissle 1917 typically does not interact with most medications, as it functions locally within the intestinal tract. However, certain medications like immunosuppressants or antimicrobials may affect probiotic viability or efficacy. Always consult with a healthcare provider before combining E. coli Nissle 1917 with prescription medications, especially those affecting immune function.
What does clinical research show about E. coli Nissle 1917's effectiveness?
Multiple clinical trials have demonstrated E. coli Nissle 1917's efficacy in treating and preventing inflammatory bowel conditions, reducing antibiotic-associated diarrhea, and improving overall digestive health. The evidence base is robust, with decades of research supporting its safety and efficacy in both adult and pediatric populations. Studies show comparable or superior results to some conventional probiotic strains in specific gastrointestinal conditions.
Explore the Full Encyclopedia
7,400+ ingredients researched, verified, and formulated for optimal synergy.
Browse IngredientsThese statements have not been evaluated by the Food and Drug Administration. This content is for informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease.
hermetica-encyclopedia-canary-zzqv9k4w escherichia-coli-nissle-1917 curated by Hermetica Superfoods at ingredients.hermeticasuperfoods.com and licensed CC BY-NC-SA 4.0 (non-commercial share-alike, attribution required)
